Globus Medical, Inc.
NYSE:GMEDMedical - Devices
-$2.10 today
- Market cap
- $9.34B
- Beta
- 0.95
- P/E (TTM)
- 17.4
- EPS (TTM)
- $4.33
Volume 1.43M
Average 1.45M
GMED Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Globus Medical, Inc.NYSE: GMED
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development dips below year-ago levels
Q2 FY2026 research & development of $36.32M fell 9.1% year over year, behind the +30.3% change in trailing-twelve-month research & development. Sequentially, it fell 0.5% from the prior quarter. Over 3 fiscal years it compounded at +36.3% a year.
Context
- Research & development amounted to 6.3% of revenue in FY2025, down 0.2 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -9.1% toward the trailing-twelve-month pace of +30.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 185M USD
- Year-over-year change
- +13.0%
- 4-year CAGR
- +17.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 185M | +13.0% |
| FY2024 | 2024-12-31 | 163.75M | +32.0% |
| FY2023 | 2023-12-31 | 124.01M | +69.8% |
| FY2022 | 2022-12-31 | 73.02M | -25.0% |
| FY2021 | 2021-12-31 | 97.35M | — |
Research & Development vs competitors
How GMED compares with its peers on the latest reported figures
- GMED's LTM Jun 2026 research & development of $184.82M is the 4th highest of the 10 companies compared; the peer median is $61.4M.
- Its year-over-year change of +30.3% is the highest of 10, against a peer median of -2.6%.
- Research & development amounts to 5.9% of revenue for GMED, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.66B | +10.1% | +8.8% | 6.4% | |
| LTM Jun 2026 | $442.9M | -0.2% | +4.1% | 5.2% | |
| FY2025 | $346M | +0.9% | +0.1% | 5.6% | |
| LTM Jun 2026 | $184.82M | +30.3% | +36.3% | 5.9% | |
| LTM Mar 2026 | $77.25M | -2.6% | +20.1% | 9.8% | |
| LTM Mar 2026 | $61.4M | -16.9% | +5.2% | 7.4% | |
| LTM Mar 2026 | $17.11M | +2.1% | +8.6% | 8.3% | |
| LTM Mar 2026 | $11.57M | -19.0% | -20.2% | 2.0% | |
| LTM Mar 2026 | $8.98M | -13.5% | +2.5% | 3.7% | |
| LTM Mar 2026 | $2.09M | -9.0% | +31.9% | 1.7% | |
| Peer median (excluding GMED) | $61.4M | -2.6% | +5.2% | 5.6% | |
Competitors are the stored peer set for GMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 958.1M | 1.02B | 1.57B | 2.52B | 2.94B |
| Cost of Revenue | 239.22M | 263.73M | 548.17M | 1.04B | 957.8M |
| Gross Profit | 718.88M | 759.12M | 1.02B | 1.48B | 1.98B |
| Gross Margin | 75.0% | 74.2% | 65.1% | 58.9% | 67.4% |
| Research & Development | 97.35M | 73.02M | 124.01M | 163.75M | 185M |
| Selling, General & Admin | 408.15M | 432.12M | 643.41M | 981.05M | 1.32B |
| Operating Expenses | 546.93M | 531.17M | 887.16M | 1.32B | 1.5B |
| Depreciation & Amortization | 69.87M | 68.25M | 144.73M | 254.02M | 276.84M |
| EBITDA | 264.73M | 304.5M | 346.58M | 473.73M | 886.74M |
| EBITDA Margin | 27.6% | 29.8% | 22.1% | 18.8% | 30.2% |
| Operating Income | 171.95M | 227.95M | 133.14M | 165.99M | 479.8M |
| Operating Margin | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% |
| Interest Income | 9.3M | 14.23M | 20.13M | 0 | 7.14M |
| Interest Expense | 0 | 0 | 0 | 4.19M | 0 |
| Other Income / Expenses | 8.45M | 15.07M | 32.25M | (45.27M) | 130.1M |
| Income Before Tax | 180.41M | 243.02M | 165.39M | 120.72M | 609.9M |
| Pre-Tax Margin | 18.8% | 23.8% | 10.5% | 4.8% | 20.8% |
| Income Tax Expense | 31.22M | 52.85M | 42.52M | 17.74M | 72M |
| Net Income | 149.19M | 190.17M | 122.87M | 102.98M | 537.9M |
| Net Margin | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
| EPS (Basic) | 1.48 | 1.89 | 1.09 | 0.76 | 3.98 |
| EPS (Diluted) | 1.44 | 1.85 | 1.07 | 0.75 | 3.92 |
| Weighted Avg Shares | 100.73M | 100.47M | 113.09M | 135.73M | 135.15M |
| Weighted Avg Shares (Diluted) | 103.62M | 102.64M | 114.63M | 137.86M | 137.22M |
Globus Medical, Inc.
NYSE:GMED
Intrinsic Alpha fair value
Locked
Current Price
$70.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.